A method for efficiently producing animal virus antibodies using ostrich eggs
By employing a method involving gradient immunization, sodium caprylate precipitation-ultrafiltration-ion exchange chromatography purification, and trehalose-mannitol as a protective agent, the problems of low purity and poor stability of ostrich egg antibodies were solved, enabling efficient and safe large-scale production. This significantly improved antibody purity and activity while reducing costs.
Patent Information
- Application Number
- CN202611399106.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-10
- Publication Date
- 2026-11-17
AI Technical Summary
In existing technologies, chicken-derived IgY antibodies have poor acid and temperature resistance, low purity, and are difficult to produce on a large scale. Egg IgY extraction yield is low, mammalian serum antibody production costs are high and the risk of pathogen contamination is high, and ostrich egg antibody purification processes are not standardized and have insufficient stability, which limits the industrial application of ostrich eggs.
Ostrich egg antibodies were prepared using a gradient immunization procedure, sodium caprylate precipitation-ultrafiltration-ion exchange chromatography purification process, and a trehalose-mannitol complex protectant. The process included three immunization dose escalations, sodium caprylate precipitation to remove lipids and impurities, ultrafiltration concentration, and DEAE-ion exchange chromatography purification. Finally, trehalose and mannitol protectants were added for vacuum freeze-drying.
It improves the purity and stability of ostrich egg antibodies, reduces production costs, extends the activity retention period of antibodies, and enables efficient and safe large-scale production. The antibody purity reaches 95%, the activity retention period can reach 24 months, the unit yield is 25 times that of chicken eggs, and the cost is reduced by 60%.
Smart Images

Figure CN123106885A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the technical field of antibody production, in particular to a method for efficiently producing animal virus antibodies by using ostrich eggs. BACKGROUND
[0002] Currently, the production technology of animal virus antibodies mainly falls into two categories.
[0003] One category is the IgY antibody production technology based on SPF chicken egg yolk. This kind of technology relies on the immune response of chickens. After immunizing SPF chickens with target antigens, IgY antibodies are extracted from the egg yolk of the chickens. However, this technology has the following defects: the molecular weight of chicken-derived IgY is about 150 kDa, and it has poor acid and heat resistance. Its activity rapidly decreases when the pH value is lower than 4.5 or the temperature exceeds 50℃. Its storage period at 4℃ is only 6 months. The extraction amount of IgY from a single chicken egg is only 15-20 mg. Large-scale production requires a large amount of egg sources, and the upper limit of production capacity is low. In addition, the antibody obtained by the existing water dilution method combined with ammonium sulfate precipitation purification process has a purity generally lower than 85%, and the residual rate of impurities is more than 10%. When used for animal disease prevention and control, it is easy to cause allergic reactions. Moreover, the process steps are complicated, and the time-consuming is as long as more than 48 hours, which is not conducive to large-scale production.
[0004] The other category is the production technology of mammalian serum antibodies. This kind of technology needs to regularly collect blood from immunized animals (such as rabbits, sheep, horses, etc.). It has the defects of high animal welfare cost, only 0.2-0.5g of antibody production per batch from a single animal, high risk of blood source pathogen contamination, and high cost of large-scale production.
[0005] Ostrich as a large bird, its yolk IgY has natural performance advantages: molecular weight of 180 kDa, more variable region antigen binding sites, stronger specificity; temperature resistance is higher than chicken IgY 15℃, activity retention rate is more than 90% under pH value 3-11 environment; single ostrich egg yolk content can reach 1.2-1.5 kg, and IgY can be extracted 300-500 mg. There are studies related to the preparation of ostrich antibodies. For example, the research of Osaka Prefectural University in Japan shows that ostrich can produce specific antibodies after being inoculated with viral antigens, and the antibodies can be enriched in egg yolk and extracted; related patents such as EP1930346A1 disclose the method for producing antibodies by using ostrich, and other patents disclose the method for purifying antibodies from yolk after immunizing ostrich with HIV and HPV antigens. However, the above existing technologies have the following shortcomings: in terms of immunization program, fixed antigen dose or simple repeated immunization is often used, and the optimized immunization scheme is not designed according to the immunization characteristics of ostrich; in terms of purification process, the existing method often directly uses the purification scheme of chicken yolk antibody, and does not fully consider the physicochemical properties of high fat content of ostrich yolk, so the purity of the obtained antibody is generally low; in terms of stability, there is no long-term storage protection scheme for ostrich IgY. At present, there is no standardized and large-scale production process suitable for the physicochemical properties of ostrich eggs in the world, which limits the industrial application of ostrich-derived IgY.
[0006] Therefore, a method for efficiently producing animal virus antibodies by using ostrich eggs is provided. SUMMARY
[0007] Therefore, the present application provides a method for efficiently producing animal virus antibodies by using ostrich eggs to solve or alleviate the technical problems in the prior art, and at least provides a beneficial choice.
[0008] The technical scheme of the present application is as follows: a method for efficiently producing animal virus antibodies by using ostrich eggs, comprising the following steps:
[0009] S1 immunization stage: select 18-24 month-old healthy female ostriches, and use gradient increasing immunization program for immunization: mix and emulsify the target animal virus inactivated antigen and Freund's complete adjuvant at 1:1, subcutaneously inject 2ml per ostrich in the neck for the first time, and the immunization dose is 200μg antigen; 14 days after the first immunization, the second immunization is carried out, the antigen is emulsified with Freund's incomplete adjuvant, and the injection dose is increased to 300μg; 7 days after the second immunization, the third immunization is carried out, and the injection dose is increased to 400μg; 7 days after the third immunization, the yolk antibody titer is detected, and when the titer is ≥1:12800, the breeding eggs are collected;
[0010] S2 Ostrich Egg Yolk Crude Extraction Stage: After surface disinfection, the collected ostrich eggs are mechanically separated from the yolks. The yolk membrane and chalaza are removed. Three volumes of pH 7.2 phosphate buffer are added according to the weight of the yolks and diluted with low-speed stirring until a uniform suspension is formed. Sodium caprylate with a final concentration of 0.1% is added as a precipitant. After slow stirring, the mixture is allowed to stand, centrifuged, and the upper fat layer and lower precipitate are discarded. The clear aqueous phase is collected to complete the crude extraction.
[0011] S3 Purification Stage: After removing residual particles by microfiltration, the crude extract is concentrated and desalted using an ultrafiltration membrane with a molecular weight cutoff of 100 kDa, and concentrated to 1 / 5 of the original volume. Then, it is separated by DEAE-agarose gel ion exchange chromatography column, eluted with a linear gradient of sodium chloride buffer, and the 280 nm UV absorbance value is monitored in real time. The eluent corresponding to the elution peak is collected, desalted by dialysis, and then freeze-dried to obtain IgY dry powder.
[0012] S4 Fixation Stage: Add 0.2% trehalose and 0.5% mannitol as cryoprotectants according to the weight of IgY dry powder, mix thoroughly, and then perform vacuum freeze-drying. After drying, vacuum seal the package in aluminum foil bags.
[0013] More preferably, the target animal virus in step S1 is African swine fever virus.
[0014] More preferably, the target animal virus in step S1 is the mandarin fish infectious spleen and kidney necrosis virus.
[0015] More preferably, the surface disinfection in step S2 is performed using 75% alcohol.
[0016] More preferably, the conditions for sodium octanoate precipitation in step S2 are: slow stirring for 15 minutes, standing at 4°C for 2 hours, and centrifugation at 8000 rpm for 20 minutes.
[0017] More preferably, the pore size of the microfiltration membrane in step S3 is 0.45 μm.
[0018] More preferably, the concentration of the sodium chloride buffer solution in step S3 is 0-0.5 mol / L.
[0019] More preferably, the product after vacuum freeze-drying in step S4 can retain its activity for up to 24 months under storage conditions at 4°C.
[0020] More preferably, the detection of egg yolk antibody titer in step S1 is performed using enzyme-linked immunosorbent assay (ELISA).
[0021] More preferably, the elution method of the DEAE-agarose gel ion exchange chromatography in step S3 is linear gradient elution.
[0022] The embodiments of the present invention have the following advantages due to the adoption of the above technical solutions:
[0023] I. This invention pioneers a "gradient incremental immunization program" adapted to the immune characteristics of ostriches. Unlike existing technologies that use fixed antigen doses or simple repeated immunizations, this invention, through a gradual increase in antigen dose over three immunizations, better aligns with the biological principles of the ostrich's immune response. This effectively activates B cell clonal expansion and antibody affinity maturation, inducing ostriches to produce high-titer, long-lasting specific antibody responses. Experimental data shows that using this immunization program, the peak yolk antibody titer can reach 1:25600, with an effective secretion period of up to 6 months, significantly outperforming the immunization effects of existing technologies.
[0024] II. This invention establishes a purification process of "sodium caprylate precipitation-ultrafiltration-ion exchange chromatography" adapted to the high lipid content and physicochemical properties of ostrich egg yolk. Existing water dilution-ammonium sulfate precipitation processes generally yield antibody purity below 85%, with residual protein levels exceeding 10%, and the process takes over 48 hours. This invention addresses the high lipid content of ostrich egg yolk by using sodium caprylate precipitation to effectively remove lipids and most of the residual proteins. Combined with ultrafiltration desalting and concentration, and DEAE-ion exchange chromatography purification, this three-step process achieves antibody purity above 95%, residual protein levels below 3%, and a recovery rate above 90%, significantly improving antibody quality and production efficiency while also significantly shortening the process time.
[0025] Thirdly, this invention is the first to apply a trehalose-mannitol composite protectant to the vacuum freeze-drying fixation of ostrich IgY. Existing chicken-derived IgY has a shelf life of only 6 months at 4°C, with rapid activity decay. This invention uses trehalose and mannitol as a composite protectant, which forms a glassy protective matrix during freeze-drying, effectively maintaining the spatial conformation of IgY and preventing antibody aggregation and loss of activity. Ostrich IgY powder treated with this composite protectant has an activity retention period of up to 24 months at 4°C, three times longer than the conventional chicken IgY storage period, significantly extending the product's shelf life and reducing storage and transportation costs.
[0026] IV. This invention offers significant advantages in terms of yield, cost, and safety. A single ostrich egg yields 350-450 mg of IgY dry powder, 25 times the yield of chicken IgY. The overall production cost is 60% lower than existing chicken IgY production processes and 90% lower than mammalian serum antibody production costs. The obtained IgY retains 90% of its activity after 30 minutes at 65°C and 85% of its activity after 1 hour in an acidic environment (pH 3.0). It can be directly added to livestock feed and drinking water without additional coating treatment. The entire process uses no toxic organic solvents, and the final product has an endotoxin content ≤0.5 EU / mg, posing no risk of allergic reactions when used for animal disease prevention and control.
[0027] The above overview is for illustrative purposes only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments, and features described above, further aspects, embodiments, and features of the invention will become readily apparent from the accompanying drawings and the following detailed description. Attached Figure Description
[0028] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0029] Figure 1 This is a process flow diagram of the present invention. Detailed Implementation
[0030] In the following description, only certain exemplary embodiments are briefly described. As those skilled in the art will recognize, the described embodiments can be modified in various ways without departing from the spirit or scope of the invention. Therefore, the drawings and description are considered to be exemplary in nature and not restrictive.
[0031] The embodiments of the present invention will now be described in detail with reference to the accompanying drawings.
[0032] like Figure 1 As shown, this embodiment of the invention provides a method for efficiently producing animal virus antibodies using ostrich eggs, comprising the following steps:
[0033] S1 Immunization Phase: Select healthy female ostriches aged 18-24 months and immunize them using a gradient immunization program: Mix the target animal virus inactivated antigen with Freund's complete adjuvant at a 1:1 ratio to emulsify. For the first immunization, inject 2ml subcutaneously into the neck of each ostrich, with an immunization dose of 200μg antigen. 14 days after the first immunization, perform a second immunization, using Freund's incomplete adjuvant to emulsify the antigen, and increase the injection dose to 300μg. 7 days after the second immunization, perform a third immunization, increasing the injection dose to 400μg. 7 days after the third immunization, test the yolk antibody titer. When the titer is ≥1:12800, start collecting hatching eggs.
[0034] In one embodiment, the target animal virus is African swine fever virus. Twenty healthy female ostriches aged 20 months were selected and immunized with inactivated African swine fever virus antigen according to the above-described gradient immunization program. Seven days after the third immunization, the yolk antibody titer was measured to be 1:25600. A total of 120 hatching eggs were collected over 30 consecutive days.
[0035] In one embodiment, the target animal virus is infectious spleen and kidney necrosis virus of mandarin fish (ISKNV). Eighteen healthy female ostriches aged 21 months were selected and immunized with inactivated ISKNV (NH0618 strain) antigen using a gradient immunization program. On day 9 after the third immunization, the yolk antibody titer reached 1:22400, and a total of 216 hatching eggs were collected over 45 days.
[0036] In one embodiment, the detection of egg yolk antibody titer is performed using enzyme-linked immunosorbent assay (ELISA).
[0037] S2 Ostrich Egg Yolk Crude Extraction Stage: After surface disinfection, the collected ostrich eggs are mechanically separated from the yolks. The yolk membrane and chalaza are removed. Three volumes of pH 7.2 phosphate buffer are added according to the weight of the yolks and diluted with low-speed stirring until a uniform suspension is formed. Sodium caprylate with a final concentration of 0.1% is added as a precipitant. After slow stirring, the mixture is allowed to stand, centrifuged, and the upper fat layer and lower precipitate are discarded. The clear aqueous phase is collected to complete the crude extraction.
[0038] In one embodiment, the surface disinfection is performed using 75% alcohol.
[0039] In one embodiment, the conditions for sodium octanoate precipitation are: slow stirring for 15 minutes, standing at 4°C for 2 hours, and centrifugation at 8000 rpm for 20 minutes.
[0040] In one embodiment, the yolks of the 120 collected eggs were surface disinfected and separated, yielding a total of 72 kg of yolks. 216 L of pH 7.2 PBS buffer was added and stirred to dilute the yolks. 72 g of sodium caprylate was added and stirred until homogeneous. After standing at 4°C for 2 hours, the mixture was centrifuged at 8000 rpm for 20 minutes and 252 L of clear aqueous phase was collected. The IgY recovery rate was found to be 92.3%.
[0041] In one embodiment, the yolks of the 216 collected eggs were surface disinfected and then separated to obtain a total yolk weight of 102 kg. 357 L of PBS buffer was added in proportion, and sodium caprylate with a final concentration of 0.1% was added as a precipitant. After slow stirring, the mixture was allowed to stand and centrifuged to collect 430 L of crude extract.
[0042] S3 Purification Stage: After removing residual particles by microfiltration, the crude extract is concentrated and desalted using an ultrafiltration membrane with a molecular weight cutoff of 100 kDa, reducing it to 1 / 5 of its original volume. It is then separated by a DEAE-agarose gel ion exchange chromatography column, eluted with a linear gradient of sodium chloride buffer, and the 280 nm UV absorbance is monitored in real time. The eluent corresponding to the elution peak is collected, desalted by dialysis, and then freeze-dried to obtain IgY dry powder.
[0043] In one embodiment, the pore size of the microfiltration membrane is 0.45 μm.
[0044] In one embodiment, the concentration of the sodium chloride buffer solution is 0-0.5 mol / L.
[0045] In one embodiment, the elution method of the DEAE-agarose gel ion exchange chromatography is linear gradient elution.
[0046] In one embodiment, 252 L of the crude aqueous extract was filtered through a 0.45 μm microfiltration membrane, concentrated to 50 L using a 100 kDa ultrafiltration membrane, separated by DEAE-agarose gel ion exchange chromatography, and the solution corresponding to the elution peak was collected. After dialyzing and lyophilization, 48.6 g of IgY dry powder was obtained, with an average extraction yield of 405 mg per egg. The purity was determined to be 96.2% by high performance liquid chromatography, and the retention rate of African swine fever virus neutralizing activity was 93.5%.
[0047] In one embodiment, 430 L of the crude extract was filtered through a 0.45 μm microfiltration membrane, concentrated using a 100 kDa ultrafiltration membrane, separated by DEAE-agarose gel ion exchange chromatography, and the solution corresponding to the elution peak was collected. After dialysis and freeze-drying, 93.8 g of ISKNV-specific IgY powder was obtained, with an average yield of 434 mg per egg.
[0048] S4 Fixation Stage: Add 0.2% trehalose and 0.5% mannitol as cryoprotectants according to the weight of IgY dry powder, mix thoroughly, and then perform vacuum freeze-drying. After drying, vacuum seal the package in aluminum foil bags.
[0049] In one embodiment, 0.2% trehalose and 0.5% mannitol were added to the African swine fever virus IgY dry powder obtained above, mixed evenly, freeze-dried and vacuum-sealed, and stored at 4°C for 12 months. The activity retention rate was 91.8%, which meets the requirements for use in the prevention and control of livestock and poultry diseases.
[0050] In one embodiment, 0.2% trehalose and 0.5% mannitol were added to the ISKNV-specific IgY dry powder obtained above, mixed evenly, freeze-dried and vacuum-sealed, and the activity test of the finished product showed that the protection rate of mandarin fish after oral administration reached 94% 7 days.
[0051] In one embodiment, the product after vacuum freeze-drying can retain its activity for up to 24 months when stored at 4°C.
[0052] In operation, this invention involves the following steps: First, healthy female ostriches aged 18-24 months are selected. The inactivated antigen of the target animal virus is emulsified with Freund's adjuvant and then immunized three times with a gradient dose of 200 μg → 300 μg → 400 μg to induce the ostriches to produce high-titer specific IgY antibodies, which accumulate in the yolk. Then, highly immunized ostrich eggs are collected, disinfected, and the yolk is separated. The yolk is diluted with 3 times the volume of PBS, and sodium caprylate is added to precipitate and remove lipids and impurities. The crude aqueous extract is collected by centrifugation. The crude extract is then purified by microfiltration, ultrafiltration concentration and desalting, and DEAE-ion exchange chromatography to obtain a high-purity IgY solution. Finally, a trehalose and mannitol composite protectant is added, and the mixture is freeze-dried under vacuum and then vacuum-sealed to obtain a stable, long-shelf-life ostrich-derived animal virus-specific IgY powder product.
[0053] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any person skilled in the art can easily conceive of various variations or substitutions within the technical scope disclosed in the present invention, and these should all be included within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.
Claims
1. A method for efficient production of antibodies against animal viruses using ostrich eggs, characterized in that, Includes the following steps: S1 Immunization Phase: Healthy female ostriches aged 18-24 months were selected, and immunization was carried out using a gradient immunization program: the target animal virus inactivated antigen was emulsified with Freund's complete adjuvant at a 1:1 ratio. For the first immunization, 2 ml of the mixture was injected subcutaneously into the neck of each ostrich, with an immunization dose of 200 μg of antigen. 14 days after the first immunization, a second immunization was performed, using Freund's incomplete adjuvant to emulsify the antigen, and the injection dose was increased to 300 μg. 7 days after the second immunization, a third immunization was performed, with the injection dose increased to 400 μg. 7 days after the third immunization, the yolk antibody titer was tested, and hatching eggs were collected when the titer was ≥1:12800. S2 Ostrich Egg Yolk Crude Extraction Stage: After surface disinfection, the collected ostrich eggs are mechanically separated from the yolks. The yolk membrane and chalaza are removed. Three volumes of pH 7.2 phosphate buffer are added according to the weight of the yolks and diluted with low-speed stirring until a uniform suspension is formed. Sodium caprylate with a final concentration of 0.1% is added as a precipitant. After slow stirring, the mixture is allowed to stand, centrifuged, and the upper fat layer and lower precipitate are discarded. The clear aqueous phase is collected to complete the crude extraction. S3 Purification Stage: After removing residual particles by microfiltration, the crude extract is concentrated and desalted using an ultrafiltration membrane with a molecular weight cutoff of 100 kDa, and concentrated to 1 / 5 of the original volume. Then, it is separated by DEAE-agarose gel ion exchange chromatography column, eluted with a linear gradient of sodium chloride buffer, and the 280 nm UV absorbance value is monitored in real time. The eluent corresponding to the elution peak is collected, desalted by dialysis, and then freeze-dried to obtain IgY dry powder. S4 Fixation Stage: Add 0.2% trehalose and 0.5% mannitol as cryoprotectants according to the weight of IgY dry powder, mix thoroughly, and then perform vacuum freeze-drying. After drying, vacuum seal the package in aluminum foil bags.
2. The method of claim 1, wherein, The target animal virus mentioned in step S1 is African swine fever virus.
3. The method of claim 1, wherein, The target animal virus mentioned in step S1 is the mandarin fish infectious spleen and kidney necrosis virus.
4. The method of claim 1, wherein, The surface disinfection described in step S2 is performed using 75% alcohol.
5. The method of claim 1, wherein, The conditions for sodium octanoate precipitation in step S2 are as follows: stir slowly for 15 minutes, let stand at 4°C for 2 hours, and centrifuge at 8000 rpm for 20 minutes.
6. The method of claim 1, wherein, The pore size of the microfiltration membrane mentioned in step S3 is 0.45 μm.
7. The method of claim 1, wherein, The concentration of the sodium chloride buffer solution in step S3 is 0-0.5 mol / L.
8. The method of claim 1, wherein, The product after vacuum freeze-drying described in step S4 can retain its activity for up to 24 months when stored at 4°C.
9. The method of claim 1, wherein, The detection of egg yolk antibody titer in step S1 is performed using enzyme-linked immunosorbent assay (ELISA).
10. The method of claim 1, wherein, The elution method for DEAE-agarose gel ion exchange chromatography in step S3 is linear gradient elution.
Citation Information
Patent Citations
Antibody produced using ostrich and method for production thereof
EP1930346A1
